Beyersdorf F, Mitrev Z, Ihnken K, Schmiedt W, Sarai K, Eckel L, Friesewinkel O, Matheis G, Buckberg G D
Department of Thoracic and Cardiovascular Surgery, Johann Wolfgang Goethe-University, Frankfurt, Germany.
J Thorac Cardiovasc Surg. 1996 Apr;111(4):873-81. doi: 10.1016/s0022-5223(96)70349-5.
Severe limb ischemia in patients having cardiac operations may occur after intraaortic balloon pump insertion, prolonged femoral vessel cannulation, percutaneous cardiopulmonary bypass, dissecting aneurysms, or emboli. Normal blood reperfusion can cause a postischemic syndrome that increases morbidity and mortality. This clinical study is based on an experimental infrastructure patterned after controlled cardiac reperfusion. (1) It tests the hypothesis that controlled limb reperfusion (i.e., modifying the composition of the initial reperfusate and the conditions of reperfusion) reduces the local and systemic complications seen after normal blood reperfusion. (2) It reports initial clinical application of this strategy in three cardiac surgery centers.
Controlled limb reperfusion was applied to 19 patients with signs of severe prolonged unilateral or bilateral ischemia (including paralysis, anesthesia, and muscle contracture); six patients (32%) were in cardiogenic shock. The mean ischemic duration was 26 +/- 6 hours. The reperfusion method includes a 30-minute infusion into the distal vessels of a normothermic reperfusate solution mixed with the patient's arterial blood (obtained proximal to the obstruction) in a 6:1 blood/reperfusate ratio. Data are mean +/- standard error of the mean.
Sixteen patients (84%) survived with salvaged and functional limbs at the time of discharge. No renal, cardiac, pulmonary, cerebral, or hemodynamic complications developed in the survivors. The three deaths occurred in patients undergoing controlled limb reperfusion while in profound postoperative cardiogenic shock; neither postischemic edema nor contracture developed in any of them.
These findings show that controlled limb reperfusion can be applied readily with standard equipment that is used for cardiac surgery and may salvage limbs while reducing postreperfusion morbidity and mortality.
接受心脏手术的患者发生严重肢体缺血可能是在主动脉内球囊反搏置入、股血管长时间插管、经皮心肺转流、动脉瘤夹层或栓子形成之后。正常血液再灌注可引发缺血后综合征,从而增加发病率和死亡率。本临床研究基于一种仿照控制性心脏再灌注构建的实验性基础设施。(1)它检验这样一个假说,即控制性肢体再灌注(即改变初始再灌注液的成分和再灌注条件)可减少正常血液再灌注后出现的局部和全身并发症。(2)它报告了该策略在三个心脏外科中心的初步临床应用情况。
对19例有严重单侧或双侧长时间缺血体征(包括瘫痪、麻木和肌肉挛缩)的患者实施控制性肢体再灌注;6例患者(32%)处于心源性休克状态。平均缺血持续时间为26±6小时。再灌注方法包括以6:1的血液/再灌注液比例向远端血管输注30分钟与患者动脉血(在阻塞近端获取)混合的常温再灌注液。数据为均值±均值标准误。
16例患者(84%)出院时存活且肢体得以挽救并恢复功能。存活者未出现肾脏、心脏、肺部、脑部或血流动力学并发症。3例死亡发生在接受控制性肢体再灌注且术后处于严重心源性休克的患者中;他们均未出现缺血后水肿或挛缩。
这些发现表明,控制性肢体再灌注可通过心脏手术常用的标准设备轻松实施,并且在降低再灌注后发病率和死亡率的同时可能挽救肢体。